Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GutHeart: Targeting Gut Microbiota to Treat Heart Failure
2015-000192-27Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Feb 2015
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of rifaximin and saccharomyces boulardii in heart failure (HF) (3 arms), sponsored by Oslo University Hospital. Primary endpoint: Baseline-adjusted left ventricular ejection fraction (LVEF). Started Feb 2015; status: completed.
02
Drugs
rifaximinsaccharomyces boulardii
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2015-000192-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000192-27.